Abstract A119: Nanocarriers with a camptothecin-mitocan co-drug suppress tumor growth and extend survival in models of chemosensitive and chemoresistant neuroblastoma
2018
Background: Neuroblastoma (NB) ranks as the most common solid tumor in infants and is responsible for 15% of all childhood cancer deaths. Chemotherapeutics used as a first-line treatment in high-risk NB patients are inherently toxic and ultimately ineffective. High-risk NB patients have Citation Format: David Guerrero, Ivan S. Alferiev, Ferro Nguyen, Peng Guan, Venkatadri Kolla, Danielle Soberman, Ilia Fishbein, Robert J. Levy, Garrett M. Brodeur, Michael Chorny. Nanocarriers with a camptothecin-mitocan co-drug suppress tumor growth and extend survival in models of chemosensitive and chemoresistant neuroblastoma [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A119.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI